State of Arthritis Medications: Some old, some new, all important
The reliable, quick reference arthritis medications guide you need to assist you and your health care team with your therapy conversations.
The JointHealth™ Medications Guide gives you information on the most commonly prescribed medications for inflammatory types of arthritis and osteoarthritis. Medication information for the following diseases is included in this year’s guide: rheumatoid arthritis, ankylosing spondylitis, juvenile arthritis, psoriatic arthritis, systemic lupus erythematosus, vasculitis, osteoarthritis, and osteoporosis.
BC PharmaCare is looking for your input on secukinumab for the treatment of ankylosing spondylitis and psoriatic arthritis
Secukinumab is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases. It is given by an injection. The drug is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about secukinumab for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
You can give input if you are a B.C. resident and have AS or PsA, a caregiver to someone with AS or PsA, or if your group represents people who live with AS or PsA.
The submission deadline is midnight on July 21, 2016. Patients and caregivers may give their input directly through the links below. Continue reading →
(Please click on the map for more information about the provincial drug formulary updates.)
The latest provincial listings, at your fingertips
Good news for people living with autoimmune arthritis in Canada!
Arthritis Consumer Experts (ACE) maps out the latest news for you: Read about the important changes to provincial drug formularies and what it means for Canadians living with autoimmune arthritis. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA). Continue reading →
Call for patient input on SEB etanercept for rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Do you have RA or AS or care for someone who does? We need your valuable input.
Health Canada defines subsequent entry biologics (SEBs) as biologic medicines that are similar to, and would enter the market after an approved innovator biologic (such as Enbrel®).
Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and are sensitive to changes in manufacturing practices. SEBs are not identical to their innovator products because their chemical characteristics cannot be precisely duplicated during the manufacturing process. Therefore, SEBs may have unique efficacy, immunogenicity, and safety profiles that are different from their innovator products.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for SEB etanercept for the treatment of rheumatoid arthritis or ankylosing spondylitis. The innovator biologic, or reference product, is etanercept (Enbrel®). Continue reading →
A team of researchers has developed Canada’s first set of systematic measures for tracking how well or poorly health systems are doing in providing services to people who have inflammatory arthritis (IA), a potentially crippling disease that is on the rise in Canada.
The researchers developed six key measures for gauging access to specialist care and initiation of treatment for people with IA, a disease grouping that includes rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis. The work is described in March issue of The Journal of Rheumatology.
People who receive early diagnosis and start of treatment have a better chance of responding well and avoiding permanent joint damage from rheumatoid arthritis (RA), the most common form of IA. There is a growing body of evidence that early detection and treatment are also crucial to good outcomes for people who have other types of IA. Continue reading →
This forum will help patients with ankylosing spondylitis and psoriatic arthritis and their family. Register now for free! The Spondyloarthritis Research Consortium of Canada and the Canadian Spondylitis Association, in collaboration with The Arthritis Society, would like to invite you to register for free to the 2016 Spondyloarthritis Patient Forum. The forum aims to help patients living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) and their family. Light refreshments will be provided.
Here are the event details:
Date: Saturday, April 30, 2016 Location: Sheraton Vancouver Wall Centre, Junior Ballroom CD
1088 Burrard Street, Vancouver Time: 3:30pm-7:00pm Cost: Free
Please note pre-registration is required. Seats are limited. You can register: Continue reading →
Souffrez-vous de spondylarthrite ankylosante ou d’arthrite psoriasique ou prodiguez-vous des soins à quelqu’un qui en souffre ? Vos commentaires seraient précieux.
Le Programme commun d’évaluation des médicaments (PCEM) invite actuellement les patients et leurs fournisseurs de soins à faire parvenir aux organismes représentant les patients leurs suggestions et commentaires sur la présentation par le fabricant du secukinumab (Cosentyx®) dans le traitement de la spondylarthrite ankylosante et de l’arthrite psoriasique. Le secukinumab est un anticorps monoclonal entièrement humain qui cible l’action de l’interleukine 17A (IL-17A), une protéine au cœur du développement des maladies inflammatoires. Le secukinumab est administré par injection.
Faisant partie de l’Agence canadienne des médicaments et des technologies de la santé, le PCEM examine avec objectivité et rigueur l’efficacité et la rentabilité des médicaments et fournit des recommandations aux régimes d’assurance-médicaments publics du Canada (à l’exception du Québec) quant à leur inscription sur la liste des médicaments assurés.
Afin de l’aider dans son processus de recommandation, le PCEM accepte la rétroaction de groupe de patients comme le comité ACE (Arthritis Consumer Experts). Nous souhaitons recueillir les commentaires de nos membres, nos abonnés et les membres de leur famille atteints de spondylarthrite ankylosante ou d’arthrite psoriasique. Les fournisseurs de soins sont également invités à nous faire parvenir leurs commentaires.
Do you have ankylosing spondylitis (AS) or psoriatic arthritis (PsA) or care for someone who does? We need your valuable input.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for secukinumab (Cosentyx®) for the treatment of ankylosing spondylitis or psoriatic arthritis. Secukinumab is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases. It is given by an injection.
The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).
To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We are calling for input from our members, subscribers and their family members who have ankylosing spondylitis or psoriatic arthritis. Caregivers are also invited to provide input.
AS Health Storylines is a self-care app for ankylosing spondylitis (AS) and associated spondyloarthritis diseases. It is developed in partnership with the Canadian Spondylitis Association, and is powered by the Health Storylines™ platform from Self Care Catalysts Inc. The Canadian Spondylitis Association is a national association to advocate for and support those living with ankylosing spondylitis, psoriatic arthritis, and associated spondyloarthritis diseases.
This app is created with input from people with AS so that the right health tools are available to you. The app allows you to record your symptoms, fatigue levels, moods, and more. Choose what you want to track to build your own summary – “My Storylines” – to learn more about your health, and to share – safely and securely – with your doctor about what happened between visits.
The following health tools in the app will help you better manage and monitor your AS or associated spondyloarthritis disease: Continue reading →
Image courtesy of Naypong at FreeDigitalPhotos.net
I can hear the sound of the spill even before it happens. Why? Because it’s a predictable outcome and it’s an oft-repeated event in our household. The noise I am referring to is the sound of a plastic pill bottle with 250 capsules hitting a tile floor and bouncing…. everywhere. The scattershot is usually followed by a few select curses and my name.
The issue is that I don’t put the childproof caps back on bottles (or any other hard-to-open bottle top, for that matter). The osteoarthritis in my thumbs and other finger joints make it a struggle-and-a-half to twist and line-up the arrows and then press down sufficiently hard while turning in the slim hope that I will actually succeed in freeing a childproof cap. Once I manage to get those dang tops off, I simply leave them off. Sometimes I rest the cover on top of the bottle, which is a deceptive practice because it appears that the top is securely closed (my bad), which leads to unfortunate incidents, such as the spill situ described above. Continue reading →